Profiel
Regina Fritsche-Danielson is currently Director at SmartCella Holding AB and SVP, Head-Research & Early Development at AstraZeneca PLC since 2019.
Former positions include Director at Fluicell AB from 2022 to 2024 and Associate Professor at the University of Gothenburg.
Education includes a doctorate from the University of Gothenburg conferred in 1993.
Actieve functies van Regina Fritsche-Danielson
| Bedrijven | Functie | Begin |
|---|---|---|
| ASTRAZENECA PLC | Hoofd Techniek/Wetenschap/O&O | 01-01-2019 |
SmartCella Holding AB
SmartCella Holding AB BiotechnologyHealth Technology Operates as a biotechnology company that develops cell therapy and delivery devices for cardiac diseases | Directeur/Bestuurslid | - |
Eerdere bekende functies van Regina Fritsche-Danielson
| Bedrijven | Functie | Einde |
|---|---|---|
| FLUICELL AB | Directeur/Bestuurslid | 28-08-2024 |
University of Gothenburg
University of Gothenburg Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Opleiding van Regina Fritsche-Danielson
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
AstraZeneca PLC
AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
University of Gothenburg
University of Gothenburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fluicell AB
Fluicell AB BiotechnologyHealth Technology Provides fluid platforms for multi-functional pipettes for cell-based pharmacology research | Health Technology |
SmartCella Holding AB
SmartCella Holding AB BiotechnologyHealth Technology Operates as a biotechnology company that develops cell therapy and delivery devices for cardiac diseases | Health Technology |
















